Detalhe da pesquisa
1.
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
Blood
; 143(6): 496-506, 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37879047
2.
Real-World and Clinical Trial Outcomes in Large B-cell Lymphoma with Axicabtagene Ciloleucel Across Race and Ethnicity.
Blood
; 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38635762
3.
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Blood
; 141(19): 2307-2315, 2023 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36821768
4.
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy.
Am J Hematol
; 99(5): 880-889, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38504387
5.
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia.
Haematologica
; 108(3): 705-716, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36226495
6.
Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
Blood
; 135(10): 735-742, 2020 03 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31945149
7.
Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1.
Haematologica
; 109(3): 982-987, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37794803
8.
A Bayesian three-parameter logistic model for early- and late-onset DLTs in oncology Phase I studies.
J Biopharm Stat
; 26(2): 339-51, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-25629564
9.
A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.
Cancer Med
; 13(5)2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38501219
10.
Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma.
Nat Med
; 30(2): 507-518, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38233586
11.
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids.
Bone Marrow Transplant
; 59(3): 366-372, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38177222
12.
A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C.
Cancer Chemother Pharmacol
; 91(4): 291-300, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36738333
13.
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659).
Oncotarget
; 14: 57-70, 2023 01 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36702329
14.
Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.
Am J Med Genet A
; 158A(1): 24-41, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22140088
15.
Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2.
Blood Adv
; 6(19): 5550-5555, 2022 10 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35470385
16.
Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma.
Expert Rev Hematol
; 14(9): 867-875, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34275403
17.
Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: a systematic literature review.
Expert Rev Hematol
; 13(8): 907-922, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32749937
18.
Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma.
Clin Cancer Res
; 26(14): 3546-3556, 2020 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32327472
19.
Correction to: A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C.
Cancer Chemother Pharmacol
; 91(4): 301, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36967405
20.
Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome.
Leuk Lymphoma
; 56(2): 395-400, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24794806